149 related articles for article (PubMed ID: 34879431)
1. The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol.
Moriya K; Imamura T; Katayama S; Kaino A; Okamoto K; Yokoyama N; Uemura S; Kitazawa H; Sekimizu M; Hiramatsu H; Usami I; Ishida H; Hasegawa D; Hama A; Moriya-Saito A; Sato A; Sasahara Y; Suenobu S; Horibe K; Hara J;
Br J Haematol; 2022 Mar; 196(5):1257-1261. PubMed ID: 34879431
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
Badowska W
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
4. [Twenty years of treating childhood acute lymphoblastic leukemia].
Pérez Martínez A; Alonso Ojembarrena A; Ramírez Orellana M; García Castro J; González-Vicent M; Contra Gómez T; Madero López L; Díaz Pérez MA
An Pediatr (Barc); 2006 Sep; 65(3):198-204. PubMed ID: 16956497
[TBL] [Abstract][Full Text] [Related]
5. Visualization of Vertebral Body Deformities in Childhood by MRI in a Boy with ALL.
Zhang XD; Madjidyar J; Peters S
Rofo; 2019 Aug; 191(8):752-753. PubMed ID: 30900230
[No Abstract] [Full Text] [Related]
6. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
[TBL] [Abstract][Full Text] [Related]
7. [Treatment results with ALL-BFM-95 protocol in children with acute lymphoblastic leukemia in Hungary].
Müller J; Kovács G; Jakab Z; Rényi I; Galántai I; Békési A; Kiss C; Nagy K; Kajtár P; Bartyik K; Masát P; Magyarosy E
Orv Hetil; 2005 Jan; 146(2):75-80. PubMed ID: 15724956
[TBL] [Abstract][Full Text] [Related]
8. [The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB 91/ALL-BFM 90m in children: analysis of efficacy and toxicity].
Karachunskiĭ AI; Miakova NV; Rumiantseva IuV; Timakov AM; Makhortykh TZh; Fechina LG; Shamardina AV; Dudkin SA; Lebedev VV; Varfolomeeva SR; Timofeeva VN; Herold R; Stakelberg A; Henze G; Rumiantsev AG
Ter Arkh; 2007; 79(7):19-26. PubMed ID: 17802785
[TBL] [Abstract][Full Text] [Related]
9. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Li C; Cai X; Chen X; Liang Y; Xia Z; Wang H
Int J Hematol; 2019 Oct; 110(4):458-465. PubMed ID: 31321731
[TBL] [Abstract][Full Text] [Related]
11. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
12. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
[TBL] [Abstract][Full Text] [Related]
14. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
15. [High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group].
Skoczen S; Klus K; Armata J; Kowalczyk J; Wisniewska-Slusarz H; Kolecki P; Derwich K; Matysiak M; Krauze A; Rokicka-Milewska R; Pawelec K; Boguslawska-Jaworska J; Juszczak K; Pisarek J; Sońta-Jakimczyk D; Tomaszewska R; Łuszczynska A; Wysocki M; Styczyński J
Med Wieku Rozwoj; 2000; 4(1 Suppl 2):23-32. PubMed ID: 12021459
[TBL] [Abstract][Full Text] [Related]
16. Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87.
Campbell M; Salgado C; Quintana J; Becker A; Vargas L; Cabrera ME; Beresi V; Rojas J; Paez E; Tapia S; Zolezzi P; Advis P
Med Pediatr Oncol; 1999 Aug; 33(2):88-94. PubMed ID: 10398182
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Koehler R; Bartram CR
Klin Padiatr; 2013 May; 225 Suppl 1():S40-4. PubMed ID: 23700054
[TBL] [Abstract][Full Text] [Related]
18. [Improved results in children with acute lymphoblastic leukemia treated with the ALL-BFM 90 protocol in the Czech Republic].
Starý J; Gajdos P; Blazek B; Ptoszková H; Mihál V; Pospísilová D; Hrstková H; Dembická D; Kopecná L; Slavík Z; Hak J; Procházková D; Zahálka F; Cerná Z; Jabali Y; Timr P; Vávra V; Mydlil J; Hrusák O; Trka J
Cas Lek Cesk; 2003; 142(7):404-9. PubMed ID: 14515443
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus reactivation and disease during treatment for childhood acute lymphoblastic leukemia.
Lauten M; Güttel C; Härtel C; Erdlenbruch B
Klin Padiatr; 2014 May; 226(3):188-9. PubMed ID: 24158893
[No Abstract] [Full Text] [Related]
20. [Comparison of the present and previously used protocol of risk stratification in children with acute lymphoblastic leukemia].
Glodkowska E; Bialas A; Jackowska T
Med Wieku Rozwoj; 2007; 11(2 Pt 1):153-8. PubMed ID: 17625285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
